Neurocysticercosis

Controversies in management

M. Cecilia Di Pentima, A. Clinton White

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Cysticercosis is a major cause of neurologic disease worldwide that is now increasingly recognized in the United States. Seizures are the most prominent symptom of central nervous system involvement. Current therapeutic interventions include the use of anticonvulsants, surgery, corticosteroids, and antiparasitic drugs, such as albendazole and praziquantel. Although antiparasitic drugs can kill the cysticerci, controlled trials in parenchymal neurocysticercosis have so far failed to document a clear clinical benefit. Further, antiparasitic drugs may actually result in neurologic deterioration in some patients. Therefore, therapy should be individualized based on the location of the cysticerci, the degree of host inflammatory response, the presumed pathogenesis, and the anticipated natural history. The objective of this article is to advance principles and standard approaches for the therapeutic intervention of neurocysticercosis. In addition, we review the pathogenesis and the natural history of cysticercosis, which provide the foundation for the management of its neurologic complications. Copyright (C) 2000 W.B. Saunders Company.

Original languageEnglish (US)
Pages (from-to)261-268
Number of pages8
JournalSeminars in Pediatric Infectious Diseases
Volume11
Issue number4
DOIs
StatePublished - 2000
Externally publishedYes

Fingerprint

Neurocysticercosis
Antiparasitic Agents
Cysticercus
Cysticercosis
Nervous System
Praziquantel
Albendazole
Nervous System Diseases
Natural History
Anticonvulsants
Adrenal Cortex Hormones
Seizures
Therapeutics
Central Nervous System

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Microbiology (medical)

Cite this

Neurocysticercosis : Controversies in management. / Di Pentima, M. Cecilia; White, A. Clinton.

In: Seminars in Pediatric Infectious Diseases, Vol. 11, No. 4, 2000, p. 261-268.

Research output: Contribution to journalArticle

@article{1219573f7f264432a235d53efc903fb3,
title = "Neurocysticercosis: Controversies in management",
abstract = "Cysticercosis is a major cause of neurologic disease worldwide that is now increasingly recognized in the United States. Seizures are the most prominent symptom of central nervous system involvement. Current therapeutic interventions include the use of anticonvulsants, surgery, corticosteroids, and antiparasitic drugs, such as albendazole and praziquantel. Although antiparasitic drugs can kill the cysticerci, controlled trials in parenchymal neurocysticercosis have so far failed to document a clear clinical benefit. Further, antiparasitic drugs may actually result in neurologic deterioration in some patients. Therefore, therapy should be individualized based on the location of the cysticerci, the degree of host inflammatory response, the presumed pathogenesis, and the anticipated natural history. The objective of this article is to advance principles and standard approaches for the therapeutic intervention of neurocysticercosis. In addition, we review the pathogenesis and the natural history of cysticercosis, which provide the foundation for the management of its neurologic complications. Copyright (C) 2000 W.B. Saunders Company.",
author = "{Di Pentima}, {M. Cecilia} and White, {A. Clinton}",
year = "2000",
doi = "10.1053/spid.2000.9641",
language = "English (US)",
volume = "11",
pages = "261--268",
journal = "Seminars in Pediatric Infectious Diseases",
issn = "1045-1870",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Neurocysticercosis

T2 - Controversies in management

AU - Di Pentima, M. Cecilia

AU - White, A. Clinton

PY - 2000

Y1 - 2000

N2 - Cysticercosis is a major cause of neurologic disease worldwide that is now increasingly recognized in the United States. Seizures are the most prominent symptom of central nervous system involvement. Current therapeutic interventions include the use of anticonvulsants, surgery, corticosteroids, and antiparasitic drugs, such as albendazole and praziquantel. Although antiparasitic drugs can kill the cysticerci, controlled trials in parenchymal neurocysticercosis have so far failed to document a clear clinical benefit. Further, antiparasitic drugs may actually result in neurologic deterioration in some patients. Therefore, therapy should be individualized based on the location of the cysticerci, the degree of host inflammatory response, the presumed pathogenesis, and the anticipated natural history. The objective of this article is to advance principles and standard approaches for the therapeutic intervention of neurocysticercosis. In addition, we review the pathogenesis and the natural history of cysticercosis, which provide the foundation for the management of its neurologic complications. Copyright (C) 2000 W.B. Saunders Company.

AB - Cysticercosis is a major cause of neurologic disease worldwide that is now increasingly recognized in the United States. Seizures are the most prominent symptom of central nervous system involvement. Current therapeutic interventions include the use of anticonvulsants, surgery, corticosteroids, and antiparasitic drugs, such as albendazole and praziquantel. Although antiparasitic drugs can kill the cysticerci, controlled trials in parenchymal neurocysticercosis have so far failed to document a clear clinical benefit. Further, antiparasitic drugs may actually result in neurologic deterioration in some patients. Therefore, therapy should be individualized based on the location of the cysticerci, the degree of host inflammatory response, the presumed pathogenesis, and the anticipated natural history. The objective of this article is to advance principles and standard approaches for the therapeutic intervention of neurocysticercosis. In addition, we review the pathogenesis and the natural history of cysticercosis, which provide the foundation for the management of its neurologic complications. Copyright (C) 2000 W.B. Saunders Company.

UR - http://www.scopus.com/inward/record.url?scp=0033753449&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033753449&partnerID=8YFLogxK

U2 - 10.1053/spid.2000.9641

DO - 10.1053/spid.2000.9641

M3 - Article

VL - 11

SP - 261

EP - 268

JO - Seminars in Pediatric Infectious Diseases

JF - Seminars in Pediatric Infectious Diseases

SN - 1045-1870

IS - 4

ER -